


One shot to lower bad cholesterol? Expert explains how new gene-editing therapy works

VERVE-102 cut LDL cholesterol by about 62% in an early trial, most helpful for those with family history, but more diverse trials needed to know if effect will last for decades.



The study is exciting because it shows that a concept once considered futuristic — a one-time genetic treatment for lifelong cholesterol control — has begun to enter human clinical testing. Photo: Unsplash

A new experimental therapy from US pharma major Eli Lilly and its subsidiary Verve Therapeutics — involving a single shot infusion that may bust LDL (low-density lipoprotein), or bad cholesterol, at one go and which sharply lowered LDL by 62% for as long as 18 months after treatment in a trial — continues to make waves among cardiologists. The therapy works by permanently switching off a cholesterol-related gene called PCSK9 inside the liver, taming LDL forever.

LDL is called “[bad cholesterol](#)” because high levels make it stick to artery walls and form hard fatty deposits called plaque. These deposits narrow the arteries and block blood flow, elevating the risk of heart attacks and strokes.

News Source:

<https://indianexpress.com/article/explained/explained-health/verve-102-gene-therapy-ldl-bad-cholesterol-expert-explains-10839064/>